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Abstract 1 
Background: Increasing skeletal muscle carnitine content represents an appealing 2 
intervention in conditions of perturbed lipid metabolism such as obesity and type 2 diabetes, 3 
but requires chronic L-carnitine feeding on a daily basis in a high-carbohydrate beverage.  4 
Objective: We investigated whether whey protein ingestion could reduce the carbohydrate 5 
load required to stimulate insulin-mediated muscle carnitine accretion.  6 
Design: Seven healthy males (24 ± 5 years, 23 ± 3 kg·m-²) ingested 80g carbohydrate (CHO), 7 
40g carbohydrate + 40g protein (CHO-PRO), or flavoured water (CON) beverages 60 min 8 
following ingestion of 4.5g L-carnitine tartrate (3g L-carnitine; 0.1% ²H3-L-carnitine). Serum 9 
insulin concentration, net forearm carnitine balance (NCB; calculated from arterialised-10 
venous and venous plasma carnitine concentrations and brachial artery plasma flow) and 11 
carnitine disappearance and appearance rates (Rd and Ra), were determined at baseline and 20 12 
min intervals for 180 min.  13 
Results: Serum insulin and plasma flow area under curve (AUC) were similarly elevated 14 
above CON (0.04 ± 0.1 and -0.5 ± 0.2) by CHO (4.5 ± 0.8; P<0.01 and 0.5 ± 0.6; P<0.05) and 15 
CHO-PRO (3.8 ± 0.6 U·L-1·min; P<0.01 and 0.4 ± 0.6 L·min; P=0.05). Plasma carnitine AUC 16 
was greater following CHO-PRO (3.5 ± 0.5) than CON (2.1 ± 0.2; P<0.05) and CHO (1.9 ± 17 
0.3 mmol·L-1·min; P<0.01). Peak NCB in CHO (135 ± 60; 120 min) was greater than CON (-18 
26 ± 40) and CHO-PRO (-113 ± 107 nmol·min-1), as was Rd AUC in CHO (35.7 ± 25.2) 19 
compared to CON (19.7 ± 15.5; P=0.07) and CHO-PRO (14.8 ± 9.6 umol·min; P<0.05). Ra 20 
was no different between trials.  21 
Conclusions: Following L-carnitine ingestion, insulin-mediated stimulation of a positive 22 
forearm carnitine balance with CHO feeding alone was acutely blunted by an isocaloric 23 
CHO-PRO beverage, suggesting that ingestion of whey protein in combination with CHO 24 
may inhibit chronic muscle carnitine accumulation.   25 
Introduction 26 
There is growing interest in the role of skeletal muscle carnitine and its associated enzymes in 27 
the perturbation of muscle lipid metabolism and aetiology of obesity and type 2 diabetes. For 28 
example, incomplete or insufficient β-oxidation of fatty acids may precede the accumulation 29 
of deleterious lipid intermediates and has been implicated in the development of skeletal 30 
muscle insulin resistance (1, 2). In line with the proposal that skeletal muscle carnitine 31 
availability is limiting to CPT1 flux and fatty acid oxidation (3), elevating muscle carnitine 32 
content via acute L-carnitine infusion (4) or chronic feeding (5) promotes physiologic and 33 
gene expression adaptations that are consistent with enhanced fat oxidation at rest and during 34 
moderate-intensity exercise. Conversely during high-intensity exercise, when mitochondrial 35 
acetyl-group provision is limited (at least partially) by the activation kinetics of the pyruvate 36 
dehydrogenase complex (PDC) enzyme (6), increasing skeletal muscle carnitine availability 37 
and acetylation improves the matching of glycolytic, PDC and mitochondrial substrate fluxes 38 
(7). The latter observation has implications for the enhancement of mitochondrial ATP 39 
delivery, such as in disease states where skeletal muscle perfusion may be impaired (8, 9).  40 
 41 
Increasing the availability of carnitine within skeletal muscle is, therefore, a useful research 42 
tool to investigate the importance of these processes in humans in vivo, as well as to 43 
manipulate muscle metabolism for health benefits. However, muscle carnitine accretion, 44 
facilitated by the Na+-dependent transporter OCTN2 (10), occurs against a 100-fold 45 
concentration gradient and hence L-carnitine feeding (11, 12) or intravenous infusion (13, 14) 46 
alone has no impact upon muscle carnitine content. Simultaneous elevation of plasma 47 
carnitine and serum insulin concentrations has proven effective in stimulating muscle 48 
carnitine uptake in healthy subjects (4, 14) and as such, a 20% increase in muscle carnitine 49 
can be achieved through twice-daily feeding of L-carnitine in a beverage containing 80 g of 50 
carbohydrate over a 12-24 week period (5, 7). However, such a large carbohydrate load per 51 
se (160 g/day) will likely affect metabolism and alter body composition (5) and so 52 
investigation into alternative oral insulinogenic formulations that can stimulate muscle 53 
carnitine accumulation using lower carbohydrate loads is warranted. For example, whey 54 
protein has previously been fed with carbohydrate to promote insulin-mediated muscle 55 
creatine retention (15) and, unlike carbohydrate, prolonged protein supplementation is less 56 
likely to influence body fat content (16). Therefore, the aim of the present study was to 57 
acutely assess forearm net carnitine balance (NCB) and uptake following oral L-carnitine 58 
ingestion in combination with 80 g of carbohydrate alone versus a protein-carbohydrate blend 59 
that would produce a similar serum insulin response.   60 
Subjects and Methods 61 
Volunteers  62 
Seven healthy, non-vegetarian males (age 24.2 ± 5.0 yrs, BMI 23.3 ± 3.1 kg·m-2) gave 63 
written informed consent and attended a routine medical screening prior to starting the study, 64 
which was approved by the University of Nottingham Medical School Ethics Committee.  65 
 66 
Experimental Protocol 67 
Subjects completed three single-blind, randomised (randomization.com) visits (Figure 1) 68 
following a 10 hour fast. Upon arrival at the University of Nottingham David Greenfield 69 
Physiology Unit, volunteers voided their bladder and laid semi-supine with one hand heated 70 
to ~55°C in an air-warming unit. This method has been shown to arterialise venous blood to 71 
within 3% of the oxygen saturation values of arterial blood (17). A cannula was placed 72 
retrograde into a dorsal vein of the heated hand for arterialised-venous blood sampling and 73 
into a deep-lying antecubital vein of the contralateral arm to sample venous blood draining 74 
the forearm muscle bed (18, 19). At t =0 min, subjects ingested 4.5 g L-carnitine tartrate 75 
(Lonza, Switzerland) with 30 mg [methyl-2H3]-L-carnitine (Cambridge Isotopes, MA, USA) 76 
in 200 ml water. At t=60 minutes, subjects were given a 500 ml beverage of either 80 g 77 
carbohydrate (CHO; Vitargo orange, Swecarb, Sweden), 40 g carbohydrate mixed with 40 g 78 
pure whey protein isolate (CHO-PRO; PRO-10.com, UK) or flavoured water (CON). The 79 
type (high molecular weight) and amount of carbohydrate used was employed previously to 80 
increase muscle carnitine content (5, 7). CHO-PRO was designed to be isocaloric and elicit a 81 
similar serum insulin response to CHO. All drinks were identically coloured and flavoured.  82 
 83 
Sampling and analysis 84 
Blood was sampled at 10 minute intervals for the determination of arterialised-venous serum 85 
insulin (Coat-A-Count Insulin; Seimens Healthcare, USA), and plasma acylcarnitine as well 86 
as both arterialised- and deep-venous whole blood glucose (Yellow Springs Instruments, 87 
Ohio) plasma free carnitine (20) concentrations and 2H3-carnitine enrichment. For the latter, 88 
plasma was purified by strong cation exchange SPE (30 mg Oasis MCX 33 µm, 80Å; 89 
Waters), dried to residue and resuspended in 0.1% formic acid for analysis by LCMSMS. 90 
Chromatography was performed in isocratic mode using 5% acetonitrile, 0.1% formic acid in 91 
water (C18 Brownlee; 2.1 x 300 mm, 5 µm). The peak area ratio of carnitine (m/z 162 → 60) 92 
to 2H3-carnitine (m/z 165 → 63) was subsequently determined in positive electrospray 93 
ionisation mode (Quattro Ultima triple quad, Micromass Ltd, UK). Brachial artery blood flow 94 
of the non-heated arm was determined by ultrasound imaging (Aplio SSA-770A, Toshiba 95 
Medical Systems) with a 12 MHz transducer synchronised to a three-lead ECG. Luminal 96 
diameter was imaged 10 cm proximal to the antecubital fossa and measured using online 97 
video callipers. Mean blood velocity was determined at the same anatomical location by 98 
integration of the pulsed-wave Doppler signal (21). Blood flow measurements were made by 99 
a single, experienced operator and values were converted to plasma flow using individual 100 
haematocrit fractional concentrations. Urine was collected from t=0 until t=180 minutes for 101 
the determination of urinary TC excretion (20). 102 
 103 
Calculations 104 
Plasma flow, F, was calculated as Blood Flow x (1 – haematocrit fraction). NBC was 105 
calculated by the Fick principle: NBC=F·[Ca-Cv’] where Ca is the arterialised-venous and Cv’ 106 
is the deep venous free carnitine concentration adjusted for non-steady state conditions (22, 107 
23). Fractional carnitine and glucose extraction were calculated to provide a flow-108 
independent marker of forearm balance: Extraction =[Ca-Cv’]/Ca·100. The rate of carnitine 109 
disappearance (Rd) across the forearm was calculated from the steady-state 
2H3-carnitine 110 
molar percent excess (MPE) using arterialised-venous plasma as the precursor pool (24): 111 
Rd=[MPEa·Ca-MPEv·Cv]·F/MPEa where MPE is the tracer-to-tracee ratio (TTR) expressed as 112 
a percentage enrichment: MPE=TTR/(1+TTR)*100. The rate of carnitine appearance, Ra, was 113 
also calculated: Ra=Rd-NCB. Consistent with small molecule pharmacokinetics, the 114 
calculations of Rd and Ra assume rapid carnitine equilibration between plasma and interstitial 115 
fluid compartments. All values were averaged over 20 min. Area under the [variable] x time 116 
curve (AUC) above baseline was integrated over 0-180 minutes.  117 
 118 
Statistics 119 
Based on our previous carnitine feeding and infusion studies (25, 26), this study was powered 120 
at 80% to detect a 10% difference in NCB in 7 subjects with an alpha level of 0.05. Time 121 
dependent variables (serum insulin and plasma free concentrations, plasma flow, NCB, 122 
carnitine extraction, MPE, Rd and Ra) were analysed using two-way repeated measures 123 
analysis of variance (ANOVA) with Bonferoni-corrected paired t-test to isolate main effects 124 
post-hoc. Urinary carnitine excretion and AUC were compared using one-way ANOVA with 125 
Tukey post-hoc. All statistical analyses were performed with GraphPad Prism 6 (GraphPad 126 
Software). Data presented are mean ± standard error of the mean (SE) for seven subjects.  127 
Results 128 
Serum Insulin and glucose extraction 129 
Serum insulin concentration was similar between CON, CHO and CHO-PRO at 0 min (7 ± 2, 130 
5 ± 1 and 6 ± 1 mU∙L-1, respectively) and did not change during CON (Figure 2A). Insulin 131 
concentration increased rapidly after CHO and CHO-PRO ingestion, peaking at 100 min (64 132 
± 10 and 72 ± 10 mU∙L-1, respectively), and remained elevated above CON thereafter. AUC 133 
in CHO (4.5 ± 0.8) and CHO-PRO (3.8 ± 0.6) was 102- and 85-fold greater, respectively, 134 
than CON (0.04 ± 0.1 U·L-1·min; P<0.01), but no different between CHO and CHO-PRO. An 135 
interaction effect was observed (P<0.001) such that glucose extraction during CHO and 136 
CHO-PRO was higher than CON from 100-180 minutes and also greater in CHO than CHO-137 
PRO at 100 and 140 minutes (Figure 2B).   138 
 139 
Plasma free, acyl and urinary total carnitine 140 
Baseline plasma arterialised-venous free carnitine (FC) concentration was no different (42 ± 141 
3, 44 ± 2 and 42 ± 3 µmol∙L-1) for CON, CHO and CHO-PRO, respectively and increased 142 
equivalently over the first hour after L-carnitine ingestion. Following the ingestion of the 143 
treatment drink, FC increased sharply in CHO-PRO and remained elevated above CHO and 144 
CON, which continued to rise steadily, for the remainder of the visit (P<0.001; Figure 3A). 145 
FC AUC during CHO-PRO (3.5 ± 0.5) was 67% and 84% greater than CON (2.1 ± 0.2; 146 
P<0.05) and CHO (1.9 ± 0.3 mmol∙L-1·min; P<0.01), respectively. Plasma acylcarnitine was 147 
unchanged in CON and CHO (P>0.05 versus baseline) but increased in CHO-PRO such that 148 
it was higher in CHO-PRO than CON between 80-120 minutes (P<0.001) and higher than 149 
CHO between 80-180 minutes (P<0.05). Urinary TC excretion was similar during CON (46 ± 150 
14 mg) and CHO (45 ± 34) but was 98 and 106% greater in CHO-PRO (92 ± 18 mg) than 151 
CON and CHO, respectively (both P<0.05).   152 
Plasma flow 153 
Plasma flow was similar at baseline for CON, CHO and CHO-PRO (40 ± 7, 47 ± 10 and 44 ± 154 
9 ml·min-1, respectively) and did not change over the first hour. A main effect of drink 155 
(P<0.05) was observed such that plasma flow was greater in CHO and CHO-PRO than CON 156 
(Figure 3B). Plasma flow AUC above baseline (0-60 min) was greater in CHO (0.5 ± 0.6; 157 
P<0.05) and tended to be greater in CHO-PRO (0.4 ± 0.6; P=0.05) than CON (-0.5 ± 0.2 158 
L·min). 159 
 160 
Net forearm carnitine balance and extraction 161 
Net carnitine balance (NCB) across the forearm is shown in Figure 3C and was unchanged 162 
over the one hour following L-carnitine ingestion. Following the treatment drink, NCB 163 
increased in CHO only (interaction effect; P<0.05), peaking at 120 min (135 ± 60) above 164 
CON (-26 ± 40; P<0.05) and CHO-PRO (-113 ± 107 nmol·min-1; P<0.05).  This resulted in a 165 
greater AUC in CHO (4.1± 3.1) than CON (-8.6 ± 3.0) and CHO-PRO (-14.6 ± 6.4 166 
µmol·min; P<0.05). Carnitine extraction was also increased (P<0.05) in CHO compared to 167 
CHO-PRO at t=100, 120 and 180 minutes and tended to be increased (P=0.09) above CON at 168 
t=120 minutes.   169 
 170 
Plasma [2H3]-carnitine enrichment, rate of disappearance and appearance  171 
Plasma [2H3]-carnitine enrichment reached a steady state after t=80 min in all trials, with a 172 
similar MPE attained in CON and CHO (~0.14%), but a slightly higher MPE of ~0.2% in 173 
CHO-PRO (Figure 4A). Plasma carnitine Rd was unchanged throughout in CON and CHO-174 
PRO but increased in CHO (Figure 4B), resulting in a 1.8 and 2.4-fold greater AUC above 175 
zero in CHO (35.7 ± 25.2) than CON (19.7 ± 15.5; P=0.07) and CHO-PRO (14.8 ± 9.6 176 
µmol·min; P<0.05), respectively. Carnitine Ra was similar and no different from zero in 177 
CON, CHO and CHO-PRO (Figure 4C).  178 
Discussion 179 
These novel data provide the most direct measurement to date of acute muscle carnitine 180 
uptake in vivo in humans and demonstrate that the ingestion of a carbohydrate beverage is 181 
able to promote a positive net carnitine balance across the forearm, indicative of accelerated 182 
muscle carnitine accretion. Moreover, replacement of some of this carbohydrate with whey 183 
protein prohibited any increase in net carnitine balance, despite inducing a similar serum 184 
insulin and plasma flow response. Thus it would appear that the mechanism by which insulin 185 
stimulates muscle carnitine transport is antagonised by a large bolus of whey protein.  186 
Studies from this lab have previously shown that elevating plasma carnitine concentration via 187 
intravenous infusion alone has no impact on muscle carnitine content (14), whilst acute (27) 188 
or chronic (11) oral dosing of L-carnitine does not affect net leg carnitine balance or muscle 189 
carnitine content, respectively. A recent study of porcine arteriovenous carnitine fluxes 190 
confirmed that net muscle carnitine uptake/efflux is negligible under normal conditions, with 191 
systemic concentrations of carnitine and acylcarnitines largely governed by gut absorption, 192 
hepatic release and renal filtration (28). The latter is consistent with the preservation of total 193 
muscle carnitine under conditions of increased metabolic flux, such as during 194 
hyperinsulinemic-euglycemic insulin clamp (4), or exercise (7). These data refute the 195 
speculated role of skeletal muscle acetylcarnitine influx/efflux in metabolic health (29, 30) 196 
and question the validity of the physiological inferences that can be made from in-vitro 197 
studies of carnitine metabolism (30, 31).  In agreement with previous in-vivo data and 198 
consistent with the high concentration gradient between plasma and tissues, carnitine 199 
ingestion in the current study had no detectable impact on NCB during CON. In contrast, 200 
CHO facilitated a positive NCB across the forearm, further validating the ingestion of L-201 
carnitine in a carbohydrate beverage as a means to augment muscle carnitine content (7). The 202 
majority of the measured plasma carnitine extraction across the forearm likely occurred into 203 
skeletal muscle (32) and thus it is possible to estimate whole-body rates of insulin-stimulated 204 
muscle carnitine accretion. Insulin was elevated from 80 to 180 minutes during CHO, over 205 
which period the NCB AUC was 7.9 µmols greater than CON. Assuming an average forearm 206 
muscle mass of 0.6 kg (18, 33) and whole-body muscle mass of 30 kg, this equates to a 207 
whole-body muscle carnitine uptake of 390 µmols above CON. This aligns well with the 370 208 
µmols (60 mg) of carnitine retention predicted from differences in urinary carnitine excretion 209 
in a previous study (26). Extended to a chronic feeding scenario, this would equate to a daily 210 
increase in muscle carnitine content of 13 µmol·kg ww-1, which would augment muscle total 211 
carnitine content stores (~5 mmol·kg ww-1) by 22% over 12 weeks. Again, this extrapolation 212 
is in good agreement with the 21% increase in muscle carnitine content reported by (5) and 213 
provides indirect validation for our values of net carnitine balance.  214 
Limb/organ balance models normally preclude definitive conclusions on whether substrate 215 
uptake, efflux, or a combination of the two has occurred (28). Here, the use of 2H3-carnitine 216 
tracer enables a more direct interrogation of muscle carnitine uptake. The average rate of 217 
forearm carnitine disappearance throughout the CON trial (~9 µmol·kg·hr-1) is very similar to 218 
estimated rates of basal muscle carnitine uptake (11.6 µmol·kg·hr-1) from compartmental 219 
modelling of intravenously-administered [3H]-carnitine kinetics (34). Peak Rd during CHO 220 
was numerically 15-fold higher than the equivalent time-point in CON and tended to be 221 
greater when compared over the entire treatment period (AUC). It could be argued that 222 
increases in NCB and Rd during CHO were related to greater plasma flow. However, 223 
carnitine fractional extraction, which does not depend on flow, was also elevated following 224 
CHO but not CON, whilst plasma flow was similarly elevated above CON in CHO-PRO 225 
(where extraction was unchanged). Moreover, peak carnitine Rd during CHO coincided with 226 
peak serum insulin concentration, suggesting that the positive NCB during CHO is more 227 
likely attributable to an up-regulation of muscle carnitine transport, rather than plasma flow.  228 
Serum insulin responses were similar between CHO and CHO-PRO and importantly, were 229 
identical over the period when forearm carnitine balance was elevated in CHO. It was thus 230 
surprising that NCB was not similarly increased during CHO-PRO. This apparent inhibition 231 
of insulin-stimulated muscle carnitine uptake is supported by the finding that Rd following 232 
CHO-PRO was supressed relative to CHO and further reflected by the augmented plasma 233 
carnitine compartment and 2-fold greater urinary carnitine excretion in CHO-PRO compared 234 
to CHO. As forearm glucose extraction was greater in CHO than CHO-PRO, it might be 235 
speculated that the absence of a positive NBC in CHO-PRO was related to differential 236 
forearm glucose metabolism. However, the difference between CHO and CHO-PRO glucose 237 
extraction relative to CON was small, and thus insufficient to explain the contrasting NCB.  238 
Considering the obligate role of the organic novel cation transporter in muscle carnitine 239 
accumulation (10, 35), it seems more plausible that the inhibition of muscle carnitine 240 
transport following CHO-PRO be related to OCTN2 activity. Known physiological inhibitors 241 
of OCTN2 include acylcarnitines (36) which have been shown to accumulate in response to 242 
increased amino acid availability as by-products of excessive amino acid oxidation or 243 
incomplete β-oxidation (37). Indeed, plasma acylcarnitine concentrations during CHO-PRO 244 
were elevated throughout the period of hyperinsulinemia and thus, could perhaps be 245 
responsible for the inhibition of muscle carnitine uptake. In line with this, plasma 246 
acylcarnitines are characteristically elevated in the insulin resistant state (38), a scenario in 247 
which muscle carnitine accumulation is purportedly compromised. Alternatively, high rates 248 
of insulin-responsive, sodium-dependent amino acid flux could restrict cationic muscle 249 
carnitine transport following CHO-PRO (39, 40), although this cannot be inferred from the 250 
current data. Why the uptake of carnitine by skeletal muscle would be inhibited by protein, 251 
given the predominant dietary source of carnitine is meat (41), is somewhat perplexing, 252 
though it should be noted that the large bolus of protein ingested in this study is excessive 253 
compared to the protein content of a normal mixed meal. Nevertheless, a slow postprandial 254 
transport of carnitine into muscle, together with a negligible rate of appearance of carnitine 255 
from muscle, is entirely consistent with the stability and slow turnover of the muscle carnitine 256 
pool (34).  257 
It has previously been suggested that amino acids could inhibit L-carnitine intestinal 258 
absorption (42).  However, the greater urinary and plasma carnitine in CHO-PRO during the 259 
current study may provide evidence to the contrary. When compared to CHO, the elevated 260 
plasma and urinary carnitine in CHO-PRO can reasonably be accounted for by the estimated 261 
difference in muscle carnitine uptake. When comparing CON and CHO-PRO trials however, 262 
during which NCB was similarly negligible, the differences in plasma and urinary carnitine 263 
would suggest that carnitine absorption was not comparable across all trials. In particular, 264 
assuming negligible intracellular release of carnitine during CON and CHO-PRO (Ra was not 265 
different from zero), the greater plasma MPE during CHO-PRO likely reflects a greater 266 
absorption of exogenous carnitine into the endogenous carnitine pool. Based on previous 267 
studies (43-45), it was expected that a 3 g dose of L-carnitine would saturate intestinal active 268 
carnitine transport and thus facilitate equivalent carnitine absorption across all trials. 269 
However, and in contrast to the suggestion that amino acids may inhibit intestinal carnitine 270 
absorption, these findings infer that protein ingestion may increase co-ingested carnitine 271 
absorption. This reconciles with the predominant dietary sources of carnitine and, given the 272 
blunting of forearm NCB in CHO-PRO, also implies that the mechanism and regulation of 273 
intestinal carnitine absorption is perhaps different from that of skeletal muscle.   274 
In Conclusion, the novel use of an acute arteriovenous forearm balance model with 2H3-L-275 
carnitine tracer methodology affirms the absence of appreciable muscle carnitine uptake (or 276 
efflux) following L-carnitine ingestion alone and confirms the efficacy of a carbohydrate 277 
beverage in promoting muscle carnitine accretion. Conversely, a carbohydrate-protein blend 278 
entirely blunted this stimulation of muscle carnitine uptake, despite comparable serum insulin 279 
concentration, plasma flow responses and apparent increased intestinal carnitine absorption. 280 
Acknowledgments  281 
CES, PLG and FBS designed research; CES and AVN conducted research and analysed data; 282 
CES wrote the paper; PLG and FBS critically revised the manuscript; FBS had primary 283 
responsibility for the final content. All authors read and approved the final manuscript. The 284 
authors have no conflict of interest to declare.285 
References 
1. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, Bain J, Stevens R, Dyck JR, 
Newgard CB, et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to 
skeletal muscle insulin resistance. Cell metabolism 2008;7(1):45-56. doi: 
10.1016/j.cmet.2007.10.013. 
2. Keung W, Ussher JR, Jaswal JS, Raubenheimer M, Lam VH, Wagg CS, Lopaschuk GD. 
Inhibition of carnitine palmitoyltransferase-1 activity alleviates insulin resistance in diet-
induced obese mice. Diabetes 2013;62(3):711-20. doi: 10.2337/db12-0259. 
3. van Loon LJC, Greenhaff PL, Constantin-Teodosiu D, Saris WHM, Wagenmakers AJM. The 
effects of increasing exercise intensity on muscle fuel utilisation in humans. The Journal of 
Physiology 2001;536(1):295-304. doi: 10.1111/j.1469-7793.2001.00295.x. 
4. Stephens FB, Constantin-Teodosiu D, Laithwaite D, Simpson EJ, Greenhaff PL. An acute 
increase in skeletal muscle carnitine content alters fuel metabolism in resting human 
skeletal muscle. The Journal of clinical endocrinology and metabolism 2006;91(12):5013-8. 
doi: 10.1210/jc.2006-1584. 
5. Stephens FB, Wall BT, Marimuthu K, Shannon CE, Constantin-Teodosiu D, Macdonald IA, 
Greenhaff PL. Skeletal muscle carnitine loading increases energy expenditure, modulates 
fuel metabolism gene networks and prevents body fat accumulation in humans. The Journal 
of Physiology 2013;591(Pt 18):4655-66. doi: 10.1113/jphysiol.2013.255364. 
6. Greenhaff PL, Campbell-O'Sullivan SP, Constantin-Teodosiu D, Poucher SM, Roberts PA, 
Timmons JA. An acetyl-group defecit limits mitochondrial ATP production at the onset of 
exercise. Biochemical Society transactions 2002;30(2). 
7. Wall BT, Stephens FB, Constantin-Teodosiu D, Marimuthu K, Macdonald IA, Greenhaff PL. 
Chronic oral ingestion of L-carnitine and carbohydrate increases muscle carnitine content 
and alters muscle fuel metabolism during exercise in humans. The Journal of Physiology 
2011;589(Pt 4):963-73. doi: 10.1113/jphysiol.2010.201343. 
8. Calvert LD, Shelley R, Singh SJ, Greenhaff PL, Bankart J, Morgan MD, Steiner MC. 
Dichloroacetate enhances performance and reduces blood lactate during maximal cycle 
exercise in chronic obstructive pulmonary disease. American journal of respiratory and 
critical care medicine 2008;177(10):1090-4. doi: 10.1164/rccm.200707-1032OC. 
9. Bauer TA, Regensteiner JG, Brass EP, Hiatt WR. Oxygen uptake kinetics during exercise are 
slowed in patients with peripheral arterial disease. J Appl Physiol 1999;87(2):809-16. 
10. Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y, Tsuji A. Molecular and 
functional identification of sodium ion-dependent, high affinity human carnitine transporter 
OCTN2. The Journal of biological chemistry 1998;273(32):20378-82. 
11. Wachter S, Vogt M, Kreis R, Boesch C, Bigler P, Hoppeler H, Krahenbuhl S. Long-term 
administration of L-carnitine to humans: effect on skeletal muscle carnitine content and 
physical performance. Clinica chimica acta; international journal of clinical chemistry 
2002;318(1-2):51-61. 
12. Vukovich MD, Costill DL, Fink WJ. Carnitine supplementation: effect on muscle carnitine and 
glycogen content during exercise. Med Sci Sports Exerc 1994;26(9):1122-9. 
13. Brass EP, Hoppel CL, Hiatt WR. Effect of intravenous L-carnitine on carnitine homeostasis 
and fuel metabolism during exercise in humans. Clinical pharmacology and therapeutics 
1994;55(6):681-92. 
14. Stephens FB, Constantin-Teodosiu D, Laithwaite D, Simpson EJ, Greenhaff PL. Insulin 
stimulates L-carnitine accumulation in human skeletal muscle. FASEB journal : official 
publication of the Federation of American Societies for Experimental Biology 
2006;20(2):377-9. doi: 10.1096/fj.05-4985fje. 
15. Steenge GR, Simpson EJ, Greenhaff PL. Protein- and carbohydrate-induced augmentation of 
whole body creatine retention in humans. J Appl Physiol 2000;89(3):1165-71. 
16. Cermak NM, Res PT, de Groot LC, Saris WH, van Loon LJ. Protein supplementation augments 
the adaptive response of skeletal muscle to resistance-type exercise training: a meta-
analysis. The American journal of clinical nutrition 2012;96(6):1454-64. doi: 
10.3945/ajcn.112.037556. 
17. Liu D, Moberg E, Kollind M, Lins PE, Adamson U, Macdonald IA. Arterial, arterialized venous, 
venous and capillary blood glucose measurements in normal man during hyperinsulinaemic 
euglycaemia and hypoglycaemia. Diabetologia 1992;35(3):287-90. 
18. Andres R, Zierler KL, Anderson HM, Stainsby WN, Cader G, Ghrayyib AS, Lilienthal JL, Jr. 
Measurement of blood flow and volume in the forearm of man; with notes on the theory of 
indicator-dilution and on production of turbulence, hemolysis, and vasodilatation by intra-
vascular injection. The Journal of clinical investigation 1954;33(4):482-504. doi: 
10.1172/jci102919. 
19. Gallen IW, Macdonald IA. Effect of two methods of hand heating on body temperature, 
forearm blood flow, and deep venous oxygen saturation. The American journal of physiology 
1990;259(5 Pt 1):E639-43. 
20. Cederblad G, Lindstedt S. A method for the determination of carnitine in the picomole range. 
Clinica chimica acta; international journal of clinical chemistry 1972;37:235-43. 
21. Hoskins PR. Measurement of arterial blood flow by Doppler ultrasound. Clinical physics and 
physiological measurement : an official journal of the Hospital Physicists' Association, 
Deutsche Gesellschaft fur Medizinische Physik and the European Federation of Organisations 
for Medical Physics 1990;11(1):1-26. 
22. Zierler KL. Theory of the use of arteriovenous concentration differences for measuring 
metabolism in steady and non-steady states The Journal of clinical investigation 
1961;40(12):2111-25. 
23. Tessari P, Inchiostro S, Biolo G, Vincenti E, Sabadin L. Effects of acute systemic 
hyperinsulinemia on forearm muscle proteolysis in healthy man. The Journal of clinical 
investigation 1991;88(1):27-33. doi: 10.1172/jci115287. 
24. Wolfe RR, Chinkes DL. Isotope Tracers in Metabolic Research: Principles and Proctice of 
Kinetic Analysis. 2nd ed. Hoboken, New Jersey: John Wiley & Sons, Inc., 2005. 
25. Stephens FB, Constantin-Teodosiu D, Laithwaite D, Simpson EJ, Greenhaff PL. A threshold 
exists for the stimulatory effect of insulin on plasma L-carnitine clearance in humans. Am J 
Physiol Endocrinol Metab 2007;292(2):E637-41. doi: 10.1152/ajpendo.00508.2006. 
26. Stephens FB, Evans CE, Constantin-Teodosiu D, Greenhaff PL. Carbohydrate ingestion 
augments L-carnitine retention in humans. J Appl Physiol 2007;102(3):1065-70. doi: 
10.1152/japplphysiol.01011.2006. 
27. Soop M, Bjorkman O, Cederblad G, Hagenfeldt L, Wahren J. Influence of carnitine 
supplementation on muscle substrate and carnitine metabolism during exercise. J Appl 
Physiol 1988;64(6):2394-9. 
28. Schooneman MG, Ten Have GA, Van Vlies N, Houten SM, Deutz NE, Soeters MR. Transorgan 
fluxes in a porcine model reveal a central role for liver in acylcarnitine metabolism. Am J 
Physiol Endocrinol Metab 2015:ajpendo 00503 2014. doi: 10.1152/ajpendo.00503.2014. 
29. Muoio DM, Noland RC, Kovalik JP, Seiler SE, Davies MN, DeBalsi KL, Ilkayeva OR, Stevens RD, 
Kheterpal I, Zhang J, et al. Muscle-specific deletion of carnitine acetyltransferase 
compromises glucose tolerance and metabolic flexibility. Cell metabolism 2012;15(5):764-
77. doi: 10.1016/j.cmet.2012.04.005. 
30. Seiler SE, Martin OJ, Noland RC, Slentz DH, DeBalsi KL, Ilkayeva OR, An J, Newgard CB, Koves 
TR, Muoio DM. Obesity and lipid stress inhibit carnitine acetyltransferase activity. Journal of 
lipid research 2014;55(4):635-44. doi: 10.1194/jlr.M043448. 
31. Seiler SE, Koves TR, Gooding JR, Wong KE, Stevens RD, Ilkayeva OR, Wittmann AH, DeBalsi 
KL, Davies MN, Lindeboom L, et al. Carnitine Acetyltransferase Mitigates Metabolic Inertia 
and Muscle Fatigue during Exercise. Cell metabolism 2015;22(1):65-76. doi: 
10.1016/j.cmet.2015.06.003. 
32. Brass EP. Pharmacokinetic considerations for the therapeutic use of carnitine in 
hemodialysis patients. Clinical therapeutics 1995;17(2):176-85; discussion 5. 
33. Allwood MJ, Hensel H, Papenberg J. Muscle and skin blood flow in the human forearm 
during insulin hypoglycaemia. The Journal of Physiology 1959;147:269-73. 
34. Rebouche CJ, Engel AG. Kinetic compartmental analysis of carnitine metabolism in the 
human carnitine deficiency syndromes. Evidence for alterations in tissue carnitine transport. 
The Journal of clinical investigation 1984;73(3):857-67. doi: 10.1172/jci111281. 
35. Treem WR, Stanley CA, Finegold DN, Hale DE, Coates PM. Primary carnitine deficiency due to 
a failure of carnitine transport in kidney, muscle, and fibroblasts. The New England journal of 
medicine 1988;319(20):1331-6. doi: 10.1056/nejm198811173192006. 
36. Ohashi R, Tamai I, Yabuuchi H, Nezu J-I, Oku A, Sai Y, Shimane M, Tsuji A. Na+-Dependent 
Carnitine Transport by Organic Cation Transporter (OCTN2): Its Pharmacological and 
Toxicological Relevance. The Journal of pharmacology and experimental therapeutics 
1999;291(2):778-84. 
37. Stephens FB, Mendis B, Shannon CE, Cooper S, Ortori CA, Barrett DA, Mansell P, Tsintzas K. 
Fish oil omega-3 fatty acids partially prevent lipid-induced insulin resistance in human 
skeletal muscle without limiting acylcarnitine accumulation. Clinical science (London, 
England : 1979) 2014;127(5):315-22. doi: 10.1042/cs20140031. 
38. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, Hwang DH, Newman JW, 
Garvey WT. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-
oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American 
women. The Journal of nutrition 2009;139(6):1073-81. doi: 10.3945/jn.108.103754. 
39. Chen GJ, Russell JB. Sodium-dependent transport of branched-chain amino acids by a 
monensin-sensitive ruminal peptostreptococcus. Applied and environmental microbiology 
1989;55(10):2658-63. 
40. White MF, Gazzola GC, Christensen HN. Cationic amino acid transport into cultured animal 
cells. I. Influx into cultured human fibroblasts. The Journal of biological chemistry 
1982;257(8):4443-9. 
41. Duran JM, Peral MJ, Calonge ML, Ilundain AA. Functional characterization of intestinal L-
carnitine transport. The Journal of membrane biology 2002;185(1):65-74. doi: 
10.1007/s00232-001-0110-5. 
42. Taylor PM. Absorbing competition for carnitine. The Journal of Physiology 2001;532(2):283-. 
doi: 10.1111/j.1469-7793.2001.0283f.x. 
43. Hamilton JW, Li BU, Shug AL, Olsen WA. Carnitine transport in human intestinal biopsy 
specimens. Demonstration of an active transport system. Gastroenterology 1986;91(1):10-6. 
44. Li B, Lloyd ML, Gudjonsson H, Shug AL, Olsen WA. The effect of enteral carnitine 
administration in humans. The American journal of clinical nutrition 1992;55(4):838-45. 
45. Harper P, Elwin CE, Cederblad G. Pharmacokinetics of bolus intravenous and oral doses of L-
carnitine in healthy subjects. European journal of clinical pharmacology 1988;35(1):69-75. 
 
 
 
 
 
 
Figures and legends 
Figure 1. Experimental protocol for study visits. 
 
Figure 2. Arterialised-venous serum insulin (A) and whole blood glucose extraction (B) 
following ingestion of 4.5 g L-carnitine-tartrate (t=0 min) and a 500 ml drink (arrow) 
containing flavoured water (CON; circles), 80 g carbohydrate (CHO; squares) or 40 g 
carbohydrate + 40 g whey protein (CHO-PRO; triangles) at t=60 min. Values are mean ± SE, 
n=7 and were compared using two-way (drink x time) ANOVA with Tukey or Bonferoni 
tests used for post-hoc subgroup comparisons following the observation of a significant main 
or interaction effect, respectively. A significant interaction effect was found for serum inuslin 
(P<0.001) and glucose extraction (P<0.001) with post-hoc subgroup comparisons denoted as 
follows: *** P<0.001 CHO vs CON; † P<0.05, †† P<0.01, ††† P<0.001 CHO-PRO vs 
CON; ‡ P<0.05, ‡‡ P<0.01 CHO vs CHO-PRO.  
 
Figure 3. Plasma arterialised-venous free carnitine concentration (A), brachial artery plasma 
flow (B) and forearm net carnitine balance (C) following ingestion of 4.5 g L-carnitine-
tartrate (t=0 min) and a 500 ml drink (arrow) containing flavoured water (CON; circles), 80 g 
carbohydrate (CHO; squares) or 40 g carbohydrate + 40 g whey protein (CHO-PRO; 
triangles) at t=60 min. Values are mean ± SE, n=7 and were compared using two-way (drink 
x time) ANOVA with Tukey or Bonferoni tests used for post-hoc subgroup comparisons 
following the observation of a significant main or interaction effect, respectively. Plasma 
flow was greater in both CHO and CHO-PRO vs CON (main effect of drink; P<0.05). A 
interaction effect (P<0.05) was found for plasma free carnitine and net carnitine balance with 
post-hoc subgroup comparisons denoted as follows: * P<0.05 CHO vs CON; ††† P<0.001 
CHO-PRO vs CON; ‡ P<0.05, ‡‡ P<0.01, ‡‡‡ P<0.001 CHO vs CHO-PRO. 
 
Figure 4. Arterialised-venous plasma [3H2]-carnitine enrichment (molar percent excess; A),  
rate of carnitine disappearance (B) and carnitine appearance (C) following ingestion of 4.5 g 
L-carnitine-tartrate (t=0 min) and a 500 ml drink (arrow) containing flavoured water (CON; 
circles), 80 g carbohydrate (CHO; squares) or 40 g carbohydrate + 40 g whey protein (CHO-
PRO; triangles) at t=60 min. Values are mean ± SE, n=7 and were compared using two-way 
(drink x time) ANOVA with Tukey or Bonferoni tests used for post-hoc subgroup 
comparisons following the observation of a significant main or interaction effect, 
respectively.  An interaction effect (P<0.001) was found for plasma [3H2]-carnitine 
enrichment with post-hoc subgroup comparisons denoted as follows:  †† P<0.01, ‡‡‡ 
P<0.001   CHO-PRO vs CON; ‡ P<0.05, ‡‡ P<0.01, ‡‡‡ P<0.001 CHO vs CHO-PRO. 
